Public Company News

Youdao to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 11

HANGZHOU, China, Jan. 28, 2026 /PRNewswire/ -- Youdao, Inc. ("Youdao" or the "Company") (NYSE:DAO), an AI-powered solutions provider specializing in artificial intelligence applications for the learning and advertising verticals, today announced that it will report its fourth quarter and fiscal ...

2026-01-28 16:30 5815

NetEase to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 11

HANGZHOU, China, Jan. 28, 2026 /PRNewswire/ -- NetEase, Inc. (NASDAQ: NTES and HKEX: 9999, "NetEase" or the "Company"), a leading internet and game services provider, today announced that it will report financial results for the fourth quarter and fiscal year 2025 onWednesday, February 11, 2026, ...

2026-01-28 16:30 7031

Hanmi Secures Export Deal with Mexican Partner Sanfer for GLP-1 Obesity Drug and More

Hanmi Signs Exclusive Partnership with New Mexican Partner Laboratorios Sanfer, Covering Efpeglenatide and Diabetes Treatments  SEOUL, South Korea, Jan. 27, 2026 /PRNewswire/ -- Hanmi is accelerating its global market entry with efpeglenatide, Korea's first domestically developed GLP-1 class obes...

2026-01-28 12:08 6781

Insilico Medicine and Qilu Pharmaceutical Reach Near $120 Million Drug Development Collaboration to Accelerate Novel Cardiometabolic Therapies

CAMBRIDGE, Mass., Jan. 27, 2026 /PRNewswire/ -- Insilico Medicine, a clinical-stage biotechnology company powered by generative AI, and Qilu Pharmaceutical Group, a major comprehensive modern pharmaceutical enterprise in China, as well as its subsidiary Shanghai Qilu Pharmaceutical Research Center...

2026-01-27 22:00 9774

Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer

SYDNEY, Jan. 27, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), today provided a clinical update from its ongoing Phase1b study evaluating paxalisib in combination with pembrolizumab and chemotherapy in patients with late-stage (Stage IV), metastatic triple-negative breast cancer (TNBC)....

2026-01-27 21:00 10553

Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease

* Novel TL1A/IL23p19 bispecific antibody targets drivers of disease pathogenesis to overcome the efficacy ceiling in inflammatory bowel disease. * License and collaboration agreement strengthen Boehringer's inflammatory disease pipeline with a potential, first-in-class, pre-clinical asset. *...

2026-01-27 18:40 8381

Innovent Announces IBI3003 (GPRC5D/BCMA/CD3 Trispecific Antibody) Receives Fast Track Designation from the U.S. FDA for Relapsed or Refractory Multiple Myeloma

SAN FRANCISCO and SUZHOU, China, Jan. 26, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabol...

2026-01-27 08:00 9383

TIAN RUIXIANG Holdings Ltd. Announces Receipt of Nasdaq Delisting Notification Regarding Minimum Bid Price Deficiency

BEIJING, Jan. 26, 2026 /PRNewswire/ -- TIAN RUIXIANG Holdings Ltd. (Nasdaq: TIRX) (the "Company" or "TRX") today announced that it had received a written notification (the "Notice") from the Listing Qualifications (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") onJanuary 20, 2026, indicat...

2026-01-27 05:30 8712

Hesai Ranks No.1 in the World for Lidar Patents by KnowMade

PALO ALTO, Calif., Jan. 26, 2026 /PRNewswire/ -- In December 2025, KnowMade, a globally renowned intellectual property (IP) research firm under Yole Group, released itsLiDAR for Automotive Patent Landscape Analysis 2025, recognizing Hesai as a leader in the global lidar industry. In the report, H...

2026-01-26 22:00 8716

Jin Medical International Ltd. To Host Management Fireside Chat

CHANGZHOU, China, Jan. 26, 2026 /PRNewswire/ -- Jin Medical International Ltd. (NASDAQ: ZJYL) ("Jin Medical", and together with all its subsidiaries, the "Company"), a NASDAQ-listed leading provider of rehabilitation medical equipment inChina, announced today that its Chief Executive Officer, tog...

2026-01-26 21:57 20795

Eastern International Ltd. Won the Bid for Its First Wind Power Construction Project Worth RMB 91.52 Million (Approx. USD 13.02 Million), Officially Marking Its Entry into the Wind Power Construction Sector

HANGZHOU, China, Jan. 26, 2026 /PRNewswire/ -- Eastern International Ltd. ("Eastern International" or the "Company") (NASDAQ: ELOG), a provider of domestic and cross-border professional logistic services and construction services including project logistic, general logistic and new energy infras...

2026-01-26 21:30 7369

Lianhe Sowell International Group Ltd Announces Strategic Plan to Establish Specialized Industry Robotics Headquarters in the UAE

SHENZHEN, China, Jan. 26, 2026 /PRNewswire/ -- Lianhe Sowell International Group Ltd (Nasdaq: LHSW) (the "Company"), a provider of industrial machine vision products and solutions inChina, today announced its strategic plan to invest in and establish its first Specialized Industry Robotics Indust...

2026-01-26 21:30 14321

Daesang's K-Food Brand O'food Launches Kimchi Ramyun at Costco and Loblaws in Canada

- Two Kimchi Ramyun Varieties Now Available Across Canada - Not just Kimchi flavor, Real Kimchi inside SEOUL, South Korea, Jan. 26, 2026 /PRNewswire/ -- Daesang's leading Korean food brand O'food has launched two Kimchi Ramyun products at Costco and Loblaws inCanada.

2026-01-26 21:00 6702

Origin Agritech to Hold Business Update & Fiscal Year 2025 Earnings Conference Call on Monday, February 2 at 8 a.m. ET

BEIJING, Jan. 26, 2026 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), a leading Chinese agricultural technology company, will announce its financial results for fiscal year 2025 onFriday, January 30. Origin will host a conference call onMonday, February 2, at 8 a...

2026-01-26 20:00 9404

Farmmi, Inc. Establishes New U.S. Subsidiary to Focus on Digital Marketing Business

LISHUI, China, Jan. 26, 2026 /PRNewswire/ -- Farmmi, Inc. (NASDAQ: FAMI) ("Farmmi" or the "Company"), today announced the establishment of a wholly-owned U.S. subsidiary, Bluesage Marketing Inc, which will conduct marketing business. This marks the Company's latest strategic development and the ...

2026-01-26 20:00 11531

HanchorBio and WuXi Biologics Enter Strategic Partnership to Advance Next-Generation Bi-and Multi-Functional Fusion Protein Pipeline

SHANGHAI, TAIPEI and SAN FRANCISCO, Jan. 26, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, and WuXi Biologics (2269.HK), a leading global Contract Research, Developm...

2026-01-26 15:00 12984

CNEY Receives Nasdaq Delisting Determination for Minimum Bid Price Deficiency

LISHUI, China, Jan. 23, 2026 /PRNewswire/ -- CN Energy Group. Inc. (NASDAQ: CNEY) ("CNEY" or the "Company"), a Nasdaq-listed company, today announced that it received a written notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that Nasdaq...

2026-01-24 06:00 10250

High-Trend International Group Announces Nearly 98% Revenue Growth for Fiscal Year 2025 and Stronger Balance Sheet

NEW YORK, Jan. 23, 2026 /PRNewswire/ -- High-Trend International Group (NASDAQ: HTCO) ("HTCO" or the "Company"), a global ocean technology company, today announced its financial results for the fiscal year endedOctober 31, 2025. * Total revenue soared 98% year-over-year to approximately US$214....

2026-01-24 05:30 15245

NaaS Technology Inc. Announces Results of Extraordinary General Meeting on January 23, 2026

BEIJING, Jan. 23, 2026 /PRNewswire/ -- NaaS Technology Inc. (Nasdaq: NAAS) ("NaaS" or the "Company"), the first U.S.-listed EV charging service company in China, is pleased to announce that at its extraordinary general meeting of shareholders held in Langfang,Hebei Province today, shareholders of ...

2026-01-24 05:05 8612

Insilico Medicine Receives IND Approval from FDA for ISM8969, an AI-empowered Potential Best-in-class NLRP3 Inhibitor

* Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) paves the way for ISM8969 clinical study inthe United States. The Phase I clinical trial aims to evaluate safety, tolerability, and pharmacokinetics profiles. * ISM8969 is a novel oral therapeutic candi...

2026-01-23 21:30 15540
1 ... 110111112113114115116 ... 744